Afqlir®▼ (aflibercept)

Welcome to the Sandoz Afqlir® (pronounced aff-clear) page for patients. 

Afqlir® is a solution which is injected into the eye to treat eye conditions in adults called:1

  • Neovascular (wet) age-related macular degeneration (wet AMD)

  • Impaired vision due to macular oedema secondary to retinal vein occlusion (branch RVO (BRVO) or central RVO (CRVO)) 

  • Impaired vision due to diabetic macular oedema (DME) 

  • Impaired vision due to myopic choroidal neovascularisation (myopic CNV) 

Afqlir® has been shown to stop the growth of new abnormal blood vessels in the eye which often leak fluid or bleed. Afqlir® can help to stabilise, and in many cases, improve the vision loss related to wet AMD, CRVO, BRVO, DME and myopic CNV.1

Patient Resources

Created to support you during your treatment with Afqlir® (aflibercept). 

Image of a medical document or informational sheet with a blue background. Text references Sandoz Patient Safety, Aflibercept, 40 mg/mL, solution for injection, and active substance Aflibercept.

Patient Guide

Your guide to help you understand how to prepare for treatment, recognise serious side effects and know when to seek urgent attention from your doctor. 

Download
Sandoz Patient Safety guide for Aflibercept 40mg/mL injection, contains instructions and information about the medication and its use.

Patient Audio Guide

Your audio version of the Patient Guide to ensure that, if you are visually impaired, you have access to the same important information regarding your treatment with Afqlir®. 

Listen
Download
A PDF document titled 'Package Leaflet: Information for the patient,' about Afglir 40 mg/ml solution for injection in a pre-filled syringe, with instructions on reporting side effects and other medical information.

Patient Information Leaflet 

A downloadable version of the leaflet that is included in every pack of Afqlir®, containing essential information about your treatment. 

Download

Information placed on this digital platform is not intended as a substitute for consultation with your healthcare professional or the information leaflet contained within the medication pack, which you should read carefully. Please consult with your healthcare professional for further information. 

AMD, age-related macular degeneration; BRVO, branch retinal vein occlusion; CNV, choroidal neovascularisation; CRVO, central retinal vein occlusion; DME, diabetic macular oedema; RVO, retinal vein occlusion. 

Reference

1. Afqlir® Patient Information Leaflet [Accessed December 2025].

Adverse events should be reported. Reporting forms and information can be found on the HPRA website (www.hpra.ie) or by emailing Rowex adverse.event.ireland@sandoz.net 

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Report any suspected adverse reactions via HPRA Pharmacovigilance; website: www.hpra.ie.

IE | December 2025 | MLR-0053-IE